Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Mirxes Pre-IPO: Challenges for Mass Adoption Become Clearer

Mirxes Pre-IPO: Early Signs of Commercialization Challenges

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Mirxes, a Singapore-based clinical-stage biotechnology company, launched its IPO to raise up to US$139m via a Hong Kong listing.</li>
<li>We look at the deal dynamics and latest developments in the early cancer screening sector in China.</li>
<li>We are of the view that there's little fundamentals supporting that valuation. Precision oncology companies have not done well in China. </li>
</ul>


Mirxes, a Singapore-based clinical-stage biotechnology company, launched its IPO to raise up to US$139m via a Hong Kong listing.
We look at the deal dynamics and latest developments in the early cancer screening sector in China.
We are of the view that there's little fundamentals supporting that valuation. Precision oncology companies have not done well in China. 


Mirxes IPO: Valuation Without Sensible Fundamentals

Mirxes Holding

Mirxes IPO: Valuation Without Sensible Fundamentals